Related Experiment Videos
The natural history of type I (severe) spinal muscular atrophy
1Department of Paediatrics and Neonatal Medicine, Hammersmith Hospital, London, U.K.
Insights
Severe spinal muscular atrophy (Werdnig-Hoffmann disease) patients with onset at birth or within two months face a poorer prognosis. This finding is crucial for future therapeutic trial designs focusing on survival length.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- Spinal muscular atrophy (SMA) type I, also known as Werdnig-Hoffmann disease, is a severe genetic neuromuscular disorder.
- Understanding the clinical spectrum and prognostic factors is essential for patient management and research.
Purpose of the Study:
- To report the clinical features of 36 patients diagnosed with SMA type I.
- To analyze survival data based on the age of onset in this cohort.
- To inform future therapeutic trial design by identifying prognostic indicators.
Main Methods:
- Retrospective analysis of clinical data from 36 patients meeting diagnostic criteria for SMA type I.
- Subgroup analysis of survival data based on age of onset (birth, within first 2 months, etc.).
Main Results:
- Detailed clinical features of the 36 SMA type I patients are presented.
- Patients with symptom onset at birth or within the first two months of life demonstrated a more uniformly poor prognosis.
- Earlier onset correlated with earlier mortality in the cohort.
Conclusions:
- Age of onset is a significant prognostic factor in SMA type I.
- Patients with early-onset SMA type I have a considerably worse survival outlook.
- These findings have implications for stratifying patients in future clinical trials and evaluating treatment efficacy based on survival.
Abstract:
The clinical features of 36 patients who satisfied the diagnostic criteria for type I (severe) spinal muscular atrophy (Werdnig-Hoffmann disease) are reported. Survival data for both the whole cohort and for groups within the cohort subdivided on the age of onset are presented. These data suggest that the patients with onset at birth or within the first 2 months of life have a more uniformly poor prognosis with earlier death. This is of potential importance in any therapeutic trials in the future whose outcome may be based on length of survival.